BR9814679A - acido ciclopentano heptanenóico, derivados de 2-heteroarilalquenila como agentes terapêuticos - Google Patents

acido ciclopentano heptanenóico, derivados de 2-heteroarilalquenila como agentes terapêuticos

Info

Publication number
BR9814679A
BR9814679A BR9814679-3A BR9814679A BR9814679A BR 9814679 A BR9814679 A BR 9814679A BR 9814679 A BR9814679 A BR 9814679A BR 9814679 A BR9814679 A BR 9814679A
Authority
BR
Brazil
Prior art keywords
radical
indicate
group
therapeutic agents
derivatives
Prior art date
Application number
BR9814679-3A
Other languages
English (en)
Inventor
Robert M Burk
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of BR9814679A publication Critical patent/BR9814679A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
    • C07C405/0058—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a not condensed ring different from a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Patente de Invenção: <B>"áCIDO CICLOPENTANO HEPTANENóICO, DERIVADOS DE 2-HETEROARILALQUENILA COMO AGENTES TERAPêUTICOS"<D>. A invenção refere-se ao uso de derivados de prostaglandinas do tipo F como hipotensivos oculares. Os compostos empregados de acordo com a invenção são representados pela fórmula (I), onde as conexões de linha ondulada indicam ou a configuração alfa (<244>) ou beta (<225>); os segmentos tracejados indicam a configuração <244>; o triângulo sólido é empregado para indicar a configuração <225>; as ligações tracejada representam uma ligação dupla, ou uma ligação única; R é um radical heteroarila substituído tendo pelo menos dois substituintes pendentes selecionados do grupo consistindo em C1 a C6 alquila; halogênio; trifluorometila; COR¹; COCF~ 3~; SO~ 2~NR¹; NO~ 2~ e CN ou pelo menos um grupo ciano; R¹ é hidrogênio ou um radical alquila inferior tendo até seis átomos de carbono, X é selecionado do grupo consistindo em -OR¹ e -N(R¹)~ 2~; Y é = O ou representa 2 radicais de hidrogênio e os 9, 11 ou 15 ésteres de alquila inferior deste; contanto que entretanto, quando o referido radical heteroarila é um radical de diclorotienila, o composto não seja um ácido 1-carboxílico ou amida deste. Certos dos compostos representados pela Fórmula (I) são novos e compreendem outro aspecto da presente invenção.
BR9814679-3A 1997-11-19 1998-11-17 acido ciclopentano heptanenóico, derivados de 2-heteroarilalquenila como agentes terapêuticos BR9814679A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/974,067 US6124344A (en) 1993-12-28 1997-11-19 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
PCT/US1998/024481 WO1999025358A1 (en) 1997-11-19 1998-11-17 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Publications (1)

Publication Number Publication Date
BR9814679A true BR9814679A (pt) 2000-10-03

Family

ID=25521544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814679-3A BR9814679A (pt) 1997-11-19 1998-11-17 acido ciclopentano heptanenóico, derivados de 2-heteroarilalquenila como agentes terapêuticos

Country Status (12)

Country Link
US (3) US6124344A (pt)
EP (1) EP1032395A1 (pt)
JP (1) JP2001522893A (pt)
KR (1) KR20010024653A (pt)
CN (1) CN1291100A (pt)
AU (1) AU1461699A (pt)
BR (1) BR9814679A (pt)
CA (1) CA2310630A1 (pt)
NO (1) NO20002217L (pt)
NZ (1) NZ504191A (pt)
RU (1) RU2217145C2 (pt)
WO (1) WO1999025358A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
US6395787B1 (en) 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
KR100437873B1 (ko) * 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
DK1527781T3 (da) 2002-08-09 2008-11-17 Taisho Pharmaceutical Co Ltd Antipruritisk middel
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
AU2003301900A1 (en) * 2002-11-13 2004-06-03 Fumie Sato Antipruritic drug
JP2005511607A (ja) * 2003-07-10 2005-04-28 アラーガン、インコーポレイテッド ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
WO2005009468A1 (ja) 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
US7906552B2 (en) * 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
CN101237885B (zh) 2005-06-03 2011-01-19 小野药品工业株式会社 神经再生和/或保护剂
WO2007056087A1 (en) * 2005-11-03 2007-05-18 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
ATE538773T1 (de) * 2008-05-14 2012-01-15 Peter Thomas Roth Labs Llc Auf prostaglandin basierende zusammensetzung und verfahren zu ihrer verwendung
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
AU2009340420A1 (en) 2008-10-29 2010-08-26 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CA2929545C (en) 2009-05-01 2019-04-09 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
BR122019025507B1 (pt) * 2013-03-15 2021-01-12 Allergan, Inc. implante intraocular biodegradável contendo prostamida e seu uso
EP4335507A3 (en) 2013-03-15 2024-06-05 Aerie Pharmaceuticals, Inc. Combination therapy
US9504653B2 (en) 2013-04-01 2016-11-29 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
SG10201701938PA (en) * 2013-04-12 2017-04-27 Allergan Inc Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
EP3669865A1 (en) 2013-10-31 2020-06-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
BR112016013594A8 (pt) * 2013-12-13 2020-05-19 Allergan Inc formas cristalinas de um composto dihidroxi ciclopentil alfa, ômega-dissubstituído, composição farmacêutica, métodos para o preparo e uso das mesmas
EP3288559B1 (en) 2015-04-30 2020-06-24 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
MX2019011784A (es) 2017-03-31 2019-11-18 Aerie Pharmaceuticals Inc Compuestos de aril ciclopropil-amino-isoquinolinil amida.
CA3112391A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
IL299577A (en) 2020-07-21 2023-03-01 Allergan Inc Intraocular implant with high prostamide loading

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
ES2159734T3 (es) * 1995-05-18 2001-10-16 Allergan Sales Inc Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
AU1461699A (en) 1999-06-07
NO20002217D0 (no) 2000-04-28
US6124344A (en) 2000-09-26
RU2217145C2 (ru) 2003-11-27
JP2001522893A (ja) 2001-11-20
NZ504191A (en) 2002-12-20
US6160129A (en) 2000-12-12
NO20002217L (no) 2000-07-18
KR20010024653A (ko) 2001-03-26
CN1291100A (zh) 2001-04-11
WO1999025358A1 (en) 1999-05-27
EP1032395A1 (en) 2000-09-06
US6248773B1 (en) 2001-06-19
CA2310630A1 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
BR9814679A (pt) acido ciclopentano heptanenóico, derivados de 2-heteroarilalquenila como agentes terapêuticos
ES446625A1 (es) Un procedimiento para la preparacion de una 4-(5- o 7-) ben-zoilindolin-2-ona.
KR930016389A (ko) No 신타제 및 시클로옥시게나제의 이중 억제제, 이들의 제조방법 및 이들을 함유하는 치료 조성물
BR0208805A (pt) Uso de um derivado de pirazolina
DE19575041I2 (de) Substituierte Acyl-Derivate von 1, 2, 3, 4-Tetrahydro-6, 7-dimethoxy-3-isoquinolin-Carbonsaeure
BR9910326A (pt) Processo para preeparar isoxazóis, composto, processo para preparar compostos, uso de compostos, e, processo para preparar tioéteres
DK0799823T3 (da) 1,2-diphenyl-pyrrolderivater, deres fremstilling og deres terapeutiske anvendelser
KR870000288A (ko) (메트)-아크릴산 에스테르의 제조방법
BR9810163A (pt) Compostos ou suas composições
DK379089A (da) Tetrahydro-1-benzoec,daaindolpropionsyre-sulfonamider, deres fremstilling og anvendelse
ES551274A0 (es) Un procedimiento para la sintesis de derivados de imidazol.
DK218684D0 (da) Imidazol-ethanol-estere
BR9806321A (pt) Processo e composição para inibir a polimerização durante a produção anaeróbica de estireno.
ATE229032T1 (de) 20-aralkyl-5,alpha,-pregnan derivate
ATE245141T1 (de) Benzolsulfonamidderivate
ES8504130A1 (es) Un metodo para preparar derivados de 4-hidroxi-2-quinolona
BR0116406A (pt) Composição para revestimento e substrato revestido com boa estabilidade ao calor de cor
BR0013346A (pt) Método para inibir polimerização prematura de monÈmero etilenicamente insaturado e composição
ES2182086T3 (es) Nuevos derivados de peptidil-arginina aldehido.
BR9713262A (pt) Produção de herbicidas de piridazina
EA200001036A1 (ru) Способы ингибирования mrp1
NO158184C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 1-fenylindazol-3-on-forbindelser og deres salter.
DK82583A (da) Furyloxazolyleddikesyrederivater og fremgangsmaader til fremstilling deraf
BR9814270A (pt) Compostos antiarrìtmicos
BR9811481A (pt) Processo para a preparação de derivados de 1,3-diazo-spiro(4,4) non-1- en-04-ona e intermediários de 1-ciano-1-acil amino ciclo-pentano

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ALLERGAN SALES, LLC (US)

B25A Requested transfer of rights approved

Free format text: ALLERGAN, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO UMA VEZ QUE O MESMO APRESENTA REIVINDICACOES QUE NAO PREENCHEM O REQUISITO DE NOVIDADE ( ARTIGO 8O COMBINADO COM ARTIGO 11 DA LEI 9279/96)